On Tuesday, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) was 3.09% up from the session before settling in for the closing price of $48.56. A 52-week range for RYTM has been $35.17 – $68.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 189.02% over the last five years. When this article was written, the company’s average yearly earnings per share was at 42.12%. With a float of $56.83 million, this company’s outstanding shares have now reached $62.39 million.
The firm has a total of 283 workers. Let’s measure their productivity. In terms of profitability, gross margin is 89.44%, operating margin of -204.04%, and the pretax margin is -199.98%.
Rhythm Pharmaceuticals Inc (RYTM) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Rhythm Pharmaceuticals Inc stocks. The insider ownership of Rhythm Pharmaceuticals Inc is 10.11%, while institutional ownership is 95.04%. The most recent insider transaction that took place on Feb 19 ’25, was worth 126,742. In this transaction Chief Financial Officer of this company sold 2,215 shares at a rate of $57.22, taking the stock ownership to the 109,929 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Chief Technical Officer sold 1,228 for $57.22, making the entire transaction worth $70,266. This insider now owns 8,509 shares in total.
Rhythm Pharmaceuticals Inc (RYTM) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.12% per share during the next fiscal year.
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) Trading Performance Indicators
You can see what Rhythm Pharmaceuticals Inc (RYTM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.36, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -1.22 in one year’s time.
Technical Analysis of Rhythm Pharmaceuticals Inc (RYTM)
Analysing the last 5-days average volume posted by the [Rhythm Pharmaceuticals Inc, RYTM], we can find that recorded value of 0.68 million was better than the volume posted last year of 0.52 million. As of the previous 9 days, the stock’s Stochastic %D was 17.05%. Additionally, its Average True Range was 2.37.
During the past 100 days, Rhythm Pharmaceuticals Inc’s (RYTM) raw stochastic average was set at 11.68%, which indicates a significant decrease from 20.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.18% in the past 14 days, which was higher than the 46.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $56.25, while its 200-day Moving Average is $51.12. Now, the first resistance to watch is $51.16. This is followed by the second major resistance level at $52.25. The third major resistance level sits at $53.88. If the price goes on to break the first support level at $48.43, it is likely to go to the next support level at $46.80. Should the price break the second support level, the third support level stands at $45.71.
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) Key Stats
There are 63,224K outstanding shares of the company, which has a market capitalization of 3.16 billion. As of now, sales total 130,130 K while income totals -260,600 K. Its latest quarter income was 41,830 K while its last quarter net income were -43,330 K.
